Low-dose spironolactone combats dyslipidemia and hepatic inflammation by modulating PCSK9 in rat model of polycystic ovarian syndrome-Reference-Cited by-同舟云学术

Low-dose spironolactone combats dyslipidemia and hepatic inflammation by modulating PCSK9 in rat model of polycystic ovarian syndrome

Published:2023-08 Issue: Volume:473 Page:116604
ISSN:0041-008X
Container-title:Toxicology and Applied Pharmacology
language:en
Short-container-title:Toxicology and Applied Pharmacology

Author:

Olaniyi Kehinde S.,Areloegbe Stephanie E.,Areola Emmanuel D.,Sabinari Isaiah W.,Fafure Adedamola A.,Agbana Richard D.,Atuma Chukwubueze L.,Shah Mohd Zahoor ul haq,Ajadi Isaac O.,Olatunji Lawrence A.

Publisher

Elsevier BV

Subject

Pharmacology,Toxicology

Reference21 articles.

1. Very low dose spironolactone protects experimentally-induced polycystic ovarian syndrome from insulin-resistant metabolic disturbances by suppressing elevated circulating testosterone;Adeyanju;Chem. Biol. Interact.,2019

2. The glucose metabolism disorder and dyslipidemia among girls with different phenotype polycystic ovary syndrome;Akbarzadeh;J. Res. Med. Sci.: Off. J. Isfahan Univ. Med. Sci.,2019

3. Association of non-alcoholic fatty liver disease and polycystic ovarian syndrome;Asfari;BMJ Open Gastroenterol.,2020

4. Hyperandrogenism in polycystic ovarian syndrome and role of CYP gene variants: a review;Ashraf;Egypt. J. Med. Human Genet.,2019

5. Polycystic ovaries are a common finding in untreated female to male transsexuals;Balen;Clin. Endocrinol.,1993

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Hepatic dysmetabolism in polycystic ovarian syndrome: impact of paraoxonase-1 modulation by butyrate;Comparative Clinical Pathology;2024-06-19

2. Screening and identification of key biomarkers associated with endometriosis using bioinformatics and next generation sequencing data analysis;2024-05-08